



ViralClear™

Merimepodib a host-
directed antiviral for
the treatment of
COVID-19

July 2020

Disclaimer



This presentation contains forward-looking statements including statements that address activities, events or developments that ViralClear Pharmaceuticals, Inc. ('ViralClear') expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, development and approvals of new products, market acceptance, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on ViralClear's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond ViralClear's control.

These risks and uncertainties, but are not limited to, the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; ViralClear's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to ViralClear's products.

ViralClear does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, ViralClear undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contents

Who are we?

COVID-19 pandemic

Preclinical data in SARS-CoV-2

Merimepodib development strategy

Summary focus and speed



ViralClearTM

Vision

ViralClear aspires to make the world a safer place by developing a therapeutic platform to address existing and emerging pathogenic threats so that people can engage in everyday life normally and safely



Who are we?

- Formed March 2020 in response to COVID-19 pandemic
- BioSig (NASDAQ BSGM) Subsidiary March 24th
- Raised \$12M May 2020
- Lead molecule merimepodib (MMPD; VX-497)
- IND submitted April 23rd; study allowed to proceed May 15th
- First Phase 2 trial initiated June 2020 in combination with remdesivir
- Virtual company with 20 employees and consultants supported by BioSig





ViralClear™

COVID-19 pandemic

COVID-19: A Global Issue



COVID-19

The Biggest Global Health and
Economic Crisis of Our Lifetimes



Confirmed Cases

>37.6M*

Deaths

>1.07M*



Confirmed Cases

>7.7M*

Deaths

>214K*

- There is no approved medical treatment yet that cures or prevents COVID-19
- So the disease progresses on with devastating health, human and economic consequences

*Johns Hopkins COVID-19 Dashboard October 12, 2020

Seeking to establish MMPD as the platform antiviral in the treatment of COVID-19



We believe MMPD has the potential to be used by a broad prescriber base across multiple settings



Hospitals



Clinics



Primary Care Physicians



Therefore, upon regulatory approval, MMPD would need a breadth of commercial support

There may not be a single silver bullet solution for COVID-19
We believe that we must focus on a multi-faceted approach...not just vaccines

Approaches include, but are not limited to:

Direct
Treatments

Antivirals for inhibition of viral replication

Immune Modulators to control inflammatory response and cytokine storm

Prevention

Vaccines

Durability of vaccines may be questionable



Dr. Anthony Fauci: “When you look at the history of coronaviruses, the common coronaviruses that cause the common cold, the reports in the literature are that the durability of immunity that’s protective ranges from 3 to 6 months to almost always less than a year. That’s not a lot of durability and protection.”



Urgent Need for Effective Direct Treatments

Goals for treating pathogenic viral threats including COVID-19

- ✓ Stop disease progression
- ✓ Hasten healing
- ✓ Accelerate viral clearance
- ✓ Stop viral shedding
- ✓ Prevention of infection
 - ✓ Vaccines
 - ✓ Prophylaxis



ViralClear

Oral IMPDH inhibitor initially developed by Vertex Pharmaceuticals Inc.

- Deprives replicating virus guanosine, essential for nucleic acid synthesis
- In vitro antiviral activity for RNA and DNA viruses
- A lead development asset for chronic hepatitis C before shelving

Drug licensed to

- Trek Therapeutics, PBC, 2016
- ViralClear Pharmaceuticals Inc., 2020

Chemistry, Manufacturing and Controls (CMC)

- Drug substance [active pharmaceutical ingredient (API)] process developed to be commercially ready for different indications
- MMPD Oral Solution formulation to conduct Phase 2 trials and pivotal trial

Clinical

- 7 Phase 1 studies for different indications – 122 health volunteers/patients exposed to MMPD
- 5 Phase 2 studies for different indications – 339 patients exposed to MMPD
 - 4 chronic hepatitis C studies and 1 psoriasis study
 - 248 chronic hepatitis C patients treated for 6 months or more




ViralClear™

Preclinical data in SARS-CoV-2

MMPD reduced SARS-CoV-2 viral titers in a Vero Cell culture model

MMPD pre-treated Vero Cells (either 4 hours or overnight [O/n]) were infected with SARS-CoV-2.




Bukreyeva N, Mantlo EK, Sattler RA, Huang C, Paessler S, Zeldis J. The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. bioRxiv doi:


<https://doi.org/10.1101/2020.04.07.028589>

In vitro, merimepodib and remdesivir in combination reduce production of infectious SARS-CoV-2 to undetectable levels

Co-treatment with MMPD + REM at concentrations as low as 2.5 μ M + 1.25 μ M reduces new production of infectious SARS-CoV-2 to undetectable levels



Co-treatment with equimolar concentrations of MMPD + REM at either 2.5 μ M or 5 μ M reduces new production of infectious SARS-CoV-2 to undetectable levels





ViralClear™

Merimepodib Development Strategy

Planned Development Strategy (Next 6 Months)

- ✓ Current COVID-19 Phase 2 trials
 - Hospitalized patients as combination with remdesivir
 - 1:1 randomization to merimepodib or placebo
 - 40 subjects -Enrolling
 - Hospitalized patients as monotherapy
 - 1:1 randomization to merimepodib or placebo
 - 40 subjects -Initiating
- ✓ All current clinical research with MMPD Oral Solution; other formulations being developed
 - Create path for
 - Emergency Use Authorization/NDA filing
 - Initiate pivotal trial
 - Initiate outpatient COVID-19 trials



ViralClear

Planned Longer Term Development (> 6 months)

- Study merimepodib's role in all stages of COVID-19
- Explore Viral Diseases of Interest and Emerging Infections
 - Dengue
 - Hemorrhagic Fever
 - Other coronavirus diseases (MERS, SARS)



ViralClear

CMC Objectives

- ✓ Onboard multiple API suppliers for NDA registration batches and commercial launch
- ✓ Identify drug product manufacturer for NDA registration batches and commercial launch
- ✓ Start the NDA filing planning process, including requesting an End Of Phase 2 CMC meeting with FDA





ViralClear™

Summary Focus and Speed

- Quickly repositioned merimepodib for COVID-19 and raised supporting capital
- Established an accomplished Development and Management team
- Top-line data on Phase 2 trials anticipated in 3Q20
- Initiate pivotal trial planned for 4Q20
- File NDA 2Q2021